Published in J Biol Chem on July 11, 2013
Heme Oxygenase-1 in Kidney Health and Disease. Antioxid Redox Signal (2016) 0.82
Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clin Proteomics (2016) 0.75
SILAC-Based Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and Impaired Energy Metabolism in Diabetic Kidney Disease. Mol Cell Proteomics (2017) 0.75
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol (2008) 38.00
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics (2002) 30.58
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics (2005) 24.04
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics (2010) 13.35
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res (2012) 13.14
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 6.79
Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One (2010) 6.61
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest (2004) 6.32
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med (2007) 5.82
Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes (2006) 5.29
Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int (2002) 3.23
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension (2003) 2.99
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension (2001) 2.61
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med (2005) 2.61
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
A microcolorimetric determination of creatine in urine by the Jaffe reaction. J Biol Chem (1954) 2.48
In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest (1990) 2.29
Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. Hypertension (2002) 2.11
AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab (2011) 2.03
Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int (2000) 2.03
Rat proximal tubule cell line transformed with origin-defective SV40 DNA: autocrine ANG II feedback. Am J Physiol (1999) 2.02
Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest (1990) 1.99
Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal Chem (2010) 1.86
Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension (2009) 1.85
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int (2008) 1.77
Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant (2005) 1.76
Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant (2012) 1.75
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol (2007) 1.73
Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol (2009) 1.64
Intrarenal AT(1) receptor and ACE binding in ANG II-induced hypertensive rats. Am J Physiol Renal Physiol (2002) 1.59
Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int (2002) 1.53
Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun (2007) 1.52
Update on tissue renin-angiotensin systems. J Mol Med (Berl) (2008) 1.50
Genetic determinants of human hypertension. Proc Natl Acad Sci U S A (1995) 1.37
Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol (2010) 1.33
Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant (2010) 1.32
Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. Am J Physiol (1999) 1.27
Plasma and urinary heme oxygenase-1 in AKI. J Am Soc Nephrol (2012) 1.25
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens (2004) 1.23
Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol (1990) 1.23
Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol (2007) 1.22
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics (2011) 1.19
Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats : possible role in renoprotection. Hypertension (2000) 1.17
Increased proximal tubular cholesterol content: implications for cell injury and "acquired cytoresistance". Kidney Int (1999) 1.15
Heme activates the heme oxygenase-1 gene in renal epithelial cells by stabilizing Nrf2. Am J Physiol Renal Physiol (2002) 1.14
The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis (1997) 1.12
Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens (1991) 1.11
Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol (2003) 1.07
Heme oxygenase isoform-specific expression and distribution in the rat kidney. Kidney Int (2001) 1.05
Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells. J Renin Angiotensin Aldosterone Syst (2007) 1.04
Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest (1991) 1.04
Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med (1993) 1.03
Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol (2003) 1.03
Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis (1999) 1.02
Obesity, insulin resistance, and renal function. Microcirculation (2007) 1.02
Verification of male infertility biomarkers in seminal plasma by multiplex selected reaction monitoring assay. Mol Cell Proteomics (2011) 1.01
Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl (1992) 1.00
Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol Med (2002) 1.00
Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. J Proteome Res (2010) 0.95
Temperature-sensitive SV40 immortalized rat proximal tubule cell line has functional renin-angiotensin system. Am J Physiol (1995) 0.94
Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res (2011) 0.94
Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int (2001) 0.92
La autoantigen mediates oxidant induced de novo Nrf2 protein translation. Mol Cell Proteomics (2011) 0.90
Redox regulation by nuclear factor erythroid 2-related factor 2: gatekeeping for the basal and diabetes-induced expression of thioredoxin-interacting protein. Mol Pharmacol (2012) 0.90
Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics (2012) 0.89
Urinary heme oxygenase-1 as a sensitive indicator of tubulointerstitial inflammatory damage in various renal diseases. Am J Nephrol (2011) 0.88
Angiotensin II amplification of alpha-adrenergic vasoconstriction: role of receptor reserve. Circ Res (1988) 0.88
Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int (1991) 0.88
Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Renal Physiol (2011) 0.86
The origin of urinary angiotensins in humans. J Am Soc Nephrol (1994) 0.84
Participation of endoplasmic reticulum stress in the pathogenesis of spontaneous glomerulosclerosis--role of intra-renal angiotensin system. Transl Res (2012) 0.83
Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a). Kidney Int Suppl (1997) 0.82
Angiotensin II: evidence for its role as an intrarenal hormone. Kidney Int Suppl (1982) 0.81
Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology (1991) 0.80
Renal handling of human apolipoprotein(a) and its fragments in the rat. Am J Kidney Dis (2001) 0.78
Angiotensin II-noradrenergic interactions in renovascular hypertensive rats. J Clin Invest (1987) 0.78
Control of the renal renin system by local factors. Kidney Int Suppl (1998) 0.77
Gene expression profiles linked to AT1 angiotensin receptors in the kidney. Physiol Genomics (2010) 0.77
Effects of AT1 and AT2 receptor blockade on angiotensin II induced apoptosis of human renal proximal tubular epithelial cells. Wien Klin Wochenschr (2002) 0.77
Urinary angiotensin II: a marker of renal tissue activity? Nephron (1994) 0.76
Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol (2007) 3.66
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov (2008) 2.80
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol (2008) 2.80
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol (2005) 2.25
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clin Chem Lab Med (2014) 2.03
Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int (2008) 1.99
Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol (2006) 1.91
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int (2008) 1.78
Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. Kidney Int (2010) 1.75
Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res (2012) 1.73
Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol (2010) 1.70
Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem (2007) 1.66
Maternal diabetes modulates renal morphogenesis in offspring. J Am Soc Nephrol (2008) 1.65
Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics (2007) 1.65
Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol (2014) 1.64
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res (2004) 1.63
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int (2011) 1.63
High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology (2002) 1.62
Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int (2004) 1.62
Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes (2007) 1.57
Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritis. J Mol Diagn (2011) 1.57
POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem (2007) 1.56
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol (2007) 1.55
More discussion on journal impact factor. Clin Chem Lab Med (2013) 1.53
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
Endothelial nitric oxide synthase gene polymorphisms and the renal hemodynamic response to L-arginine. Kidney Int (2008) 1.50
B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res (2006) 1.50
Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. Cancer Epidemiol Biomarkers Prev (2004) 1.49
Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension (2010) 1.45
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
Theranos phenomenon: promises and fallacies. Clin Chem Lab Med (2015) 1.42
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem (2012) 1.41
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. Tumour Biol (2005) 1.41
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res (2007) 1.40
Association between Echinococcus granulosus infection and cancer risk - a pilot study in Cyprus. Clin Chem Lab Med (2016) 1.39
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res (2008) 1.37
The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem (2009) 1.36
Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol (2006) 1.35
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
Functional roles of human kallikrein-related peptidases. J Biol Chem (2009) 1.33
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics (2008) 1.32
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem (2010) 1.32
A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem (2006) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem (2011) 1.30
Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol (2002) 1.30
Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res (2011) 1.29
Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail (2009) 1.29
BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet (2011) 1.28
Human tissue kallikreins: the cancer biomarker family. Cancer Lett (2007) 1.28
Down-regulation of dicer expression in ovarian cancer tissues. Clin Biochem (2009) 1.25
The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes (2007) 1.24
A flexible genome-wide bootstrap method that accounts for ranking and threshold-selection bias in GWAS interpretation and replication study design. Stat Med (2011) 1.23
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res (2006) 1.23
Proteomic analysis of human cervico-vaginal fluid. J Proteome Res (2007) 1.23
Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol (2007) 1.22
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res (2007) 1.22
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol (2007) 1.21
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol (2004) 1.21
Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res (2003) 1.20
Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics (2011) 1.19
Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics (2009) 1.19
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate (2003) 1.19
Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol (2007) 1.19
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem (2005) 1.18
Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes (2002) 1.17
Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care (2009) 1.17
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol (2008) 1.15
High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology (2003) 1.14
The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant (2008) 1.14
Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn (2006) 1.14
Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun (2003) 1.14
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem (2002) 1.13
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem (2006) 1.13
Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget (2012) 1.13
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
A repository for "rare" tumor markers? Clin Chem Lab Med (2014) 1.12
Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem (2008) 1.11
Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol (2010) 1.11
Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol (2002) 1.11
Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc Res (2008) 1.11
Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res (2009) 1.11
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol (2004) 1.11
Eight-Hour Continuous Normothermic Ex Vivo Kidney Perfusion Is a Safe Preservation Technique for Kidney Transplantation: A New Opportunity for the Storage, Assessment, and Repair of Kidney Grafts. Transplantation (2016) 1.10
Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol (2009) 1.10